Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs
Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers, with $52.0 million in upfront payments Extended ant ...
Diamyd Medical AB: Diamyd Medical announces expanded financial support from Breakthrough T1D
Diamyd Medical will receive USD 1.75 million in expanded collaboration support from Breakthrough T1D (formerly JDRF), the world's leading Type 1 Diabetes ...